Zhengye Biotechnology Holding Ltd (ZYBT)
↓ Download CSV- Sector Manufacturing
- Incorporated F4
In fiscal 2025, Zhengye Biotechnology Holding Ltd reported revenue of 116.36M CNY, down 37.6% from the prior year. The company ran a net loss, with a net margin of -60.0% and a gross margin of 20.5%. It held 436.47M CNY in total assets against 129.76M CNY in total liabilities.
Key ratios (FY2025)
20.5%
Gross margin
-60.6%
Operating margin
-60.0%
Net margin
-22.8%
Return on equity
-37.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 116.36M CNY | 186.36M CNY | 211.65M CNY | 260.27M CNY | — |
| Cost of Revenue | 92.49M CNY | 95.06M CNY | 94.14M CNY | 112.39M CNY | — |
| Gross Profit | 23.87M CNY | 91.30M CNY | 117.51M CNY | 147.88M CNY | — |
| Operating Income | -70.51M CNY | 16.44M CNY | 44.99M CNY | 65.83M CNY | — |
| Net Income | -69.78M CNY | 11.31M CNY | 31.46M CNY | 46.73M CNY | — |
| EPS (Diluted) | — | 0.25 CNY | 0.69 CNY | 1.02 CNY | — |
| Total Assets | 436.47M CNY | 493.25M CNY | 499.89M CNY | — | — |
| Total Liabilities | 129.76M CNY | 140.71M CNY | 160.62M CNY | — | — |
| Shareholders' Equity | 306.71M CNY | 352.54M CNY | 339.27M CNY | 356.87M CNY | 318.84M CNY |
| Cash & Equivalents | — | 18.60M CNY | 15.07M CNY | — | — |
| Operating Cash Flow | 13.33M CNY | 41.05M CNY | 48.18M CNY | 17.34M CNY | — |
| Capital Expenditures | 1.01M CNY | 13.59M CNY | 7.40M CNY | 27.33M CNY | — |
| Shares Outstanding | 47.35M | 45.67M | 45.67M | 45.67M | — |